Ginkgo Bioworks (DNA)

What Could Go Wrong

1. 01Platform adoption risk - synthetic biology remains nascent with uncertain commercialization timelines; customers may develop in-house capabilities rather than outsourcing
2. 02Technology obsolescence - rapid advances in AI-driven protein design, CRISPR tools, and competing automation platforms could erode competitive moat
3. 03Regulatory uncertainty - evolving biosafety regulations and engineered organism approval pathways create commercialization barriers for customer products
4. 04Large pharma in-house capabilities - companies like Amgen, Novo Nordisk building internal cell engineering platforms with superior resources
5. 05Specialized competitors - Zymergen's failure demonstrates platform model risks; Twist Bioscience, Codexis, and Absci compete in specific verticals with focused approaches
6. 06Customer concentration - loss of major programs or shift to insourcing by key customers would materially impact revenue
7. 07Liquidity runway - with $400M+ annual cash burn and current ratio of 4.39, the company likely needs additional capital within 12-18 months absent significant improvement in cash flow
8. 08Equity dilution risk - likely requires future equity raises at depressed valuations given market cap of only $500M, highly dilutive to existing shareholders

DNA Chart

My Notes

• Speculative growth investors with high risk tolerance and long time horizons.
• High sensitivity through multiple channels: (1) Higher rates compress valuation multiples for unprofitable growth companies…
• Watch on earnings: Biotech venture capital funding volumes - leading indicator of customer budget availability, Biopharma R&D spending trends - correlates with outsourced cell engineering demand, Federal funds rate and 10-year Treasury yield - directly impacts valuation multiples and customer financing costs.